Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from July 1, 2025

Partial Published before the outcome was known, scored automatically when the window closed on September 29, 2025.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted

$77.60 – $78.95Entry zone — fair-value band

$80.49Published — price the day we called it

$93.25Target — the price the thesis aimed for

$86.24Peak — highest point inside the window, not a realized return

$77.91Window close — end-of-window price, context only

What happened

Partial

Reached 40% of the predicted growth at its peak, without hitting the target.

Peak price

$86.24

peak on August 22, 2025 — not a realized return

Peak gain

+7.2%

peak, from the publication price

Window close

$77.91

end-of-window price, context only

Days to target

—

Window

July 1, 2025 – September 29, 2025

The thesis — published July 1, 2025

Predicted growth

+18%

over the measurement window

Target price

$93.25

the price the thesis aimed for

Entry zone

$77.60 – $78.95

the fair-value band we waited for

Price at publication

$80.49

published July 1, 2025

Confidence

85%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Merck is getting strong reviews from market trackers, scoring near perfect marks for recent price strength and investor mood before it reports earnings in late July. Research firm Zacks expects the company to beat forecasts again. Buying interest has jumped sharply, showing more demand than usual. Meanwhile, cancer drug Keytruda and its vaccines bring in steady cash, making dips to the low 80 dollar range a cheap way to aim for about 18% upside toward the high 90s within three months.

Primary drivers

Near-perfect scores tell us big investors are still buying shares steadily.
Strong chance of another earnings beat in July could push the price higher.
Surge in buying volume signals the recent uptrend may keep going.
Keytruda and vaccines bring reliable money, shielding the firm from economic swings.

How it played out

MRK: the target was not reached

Lyra published MRK at 80.49 on 2025-07-01, with 18% expected growth toward 93.25. The thesis pointed to strong price strength and investor mood, a possible July earnings beat, heavier buying volume, and steady cash from Keytruda and vaccines. It framed dips in the low 80 dollar range as the setup.

Inside the window from 2025-07-01 to 2025-09-29, MRK peaked at 86.24 on 2025-08-22. That was a 7.2% gain, but it stayed below 93.25. The stock ended at 77.91. The thesis partially played out on direction at the peak, but it missed the target.

What happened during the window

On 2025-07-09, Merck announced an agreement to buy Verona Pharma for about $10 billion. On 2025-07-29, Merck reported second-quarter results and announced a cost-cutting plan after a revenue miss.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals